2-(2-methylpropyl)-4-methylfuran | 126861-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-(2-methylpropyl)-4-methylfuran
• 英文别名: 2-Isobutyl-4-methylfuran；4-methyl-2-(2-methylpropyl)furan
• CAS: 126861-09-4
• 化学式: C₉H₁₄O
• 分子量: 138.21
• InChiKey: OQMOSIGMGVLRHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-methylpropyl)-4-methylfuran 、 N-甲基甲酰苯胺 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以88%的产率得到5-isobutyl-3-mehtyl-2-furancarbaldehyde
  参考文献：
  名称：

  Tsukasa, Hidetaka, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 2.3.4., p. 532

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-Dimethyl-1-hepten-4-ol 在 重铬酸吡啶 、 硫酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 正戊烷 为溶剂， 反应 21.0h， 生成 2-(2-methylpropyl)-4-methylfuran
  参考文献：
  名称：

  5-isobutyl-3-methyl-2-furancarbaldehyde, a new monoterpenoid from the essential oil of tagetes glandulifera schrank

  摘要：

  DOI：

  10.1016/s0040-4039(01)80101-5

文献信息

• ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS
  申请人：TECHNISCHE UNIVERSITÄT BERLIN

  公开号：US20150376120A1

  公开（公告）日：2015-12-31

  Antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which include carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections are also disclosed.

  具有一般式（I）的抗生素活性化合物的特征，其中X1、BB、BC、BD、BE和X2是具有D1、D2、D3、D4或D5连接器的构建块，包括碳、硫、氮、磷和/或氧原子，并且共价连接BA和BB、BB和BC、BC和BD、BD和BE以及BE和BF的基团，其中特别是构建块BC包括一种氨基酸衍生物。该化合物用于治疗疾病的方法，特别是用于治疗细菌感染的方法。
• AMORPHOUS COMPOSITION
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1829549A1

  公开（公告）日：2007-09-05

  To provide an amorphous composition for nasal administration or for administration by adhering to oral mucosa in which absorption property and chemical and physical stabilities of (2R)-N-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-[(4R)-3-tert-butoxycarbonylthiazolidin-4-ylcarbonylamino]propanamide which is useful as an N type calcium channel inhibitor are improved. A preparation comprising the amorphous composition of the present invention has been found to be excellent in physical stability and chemical stability and to be useful as a nasal preparation or a preparation for adhering to the oral mucosa. As a result, the resulting preparation has a high BA value and is useful for prevention and/or the treatment of a disease mediated by the N type calcium channel including pain (such as neuropathic pain, cancerous pain, intractable pain, postoperative pain, acute pain, chronic pain, neuralgia and infectious pain).

  提供一种用于鼻腔给药或粘附在口腔粘膜上给药的无定形组合物，该组合物改善了作为 N 型钙通道抑制剂的 (2R)-N-(1-苄基哌啶-4-基)-3-环己基甲基硫-2-[(4R)-3-叔丁氧羰基噻唑烷-4-基羰基氨基]丙酰胺的吸收性能和化学及物理稳定性。 研究发现，包含本发明无定形组合物的制剂具有优异的物理稳定性和化学稳定性，可用作鼻腔制剂或粘附在口腔粘膜上的制剂。因此，本发明制剂具有很高的 BA 值，可用于预防和/或治疗由 N 型钙通道介导的疾病，包括疼痛（如神经性疼痛、癌痛、难治性疼痛、术后疼痛、急性疼痛、慢性疼痛、神经痛和感染性疼痛）。
• Fused heterotricyclic organic compounds, pharmaceutical compositions, and medical uses thereof
  申请人：Alevere Medical Corporation

  公开号：US10888563B2

  公开（公告）日：2021-01-12

  The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.

  本发明提供了融合杂环有机化合物（如二氢吡唑并哒嗪酮）、含有此类化合物的组合物、医药包以及使用此类化合物和组合物塑身和/或减少受试者脂肪的方法。
• Heterocyclization of ?,?-dichloro ketones as a method for the synthesis of furan derivatives
  作者：�. I. Mamedov、A. G. Ismailov、S. I. Kozhushkov、N. S. Zefirov

  DOI：10.1007/bf00529363

  日期：1992.3
• Amorphous Composition
  申请人：Masuda Hideo

  公开号：US20080096924A1

  公开（公告）日：2008-04-24

  To provide an amorphous composition for nasal administration or for administration by adhering to oral mucosa in which absorption property and chemical and physical stabilities of (2R)—N-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-[(4R)-3-tert-butoxycarbonylthiazolidin-4-ylcarbonylamino]propanamide which is useful as an N type calcium channel inhibitor are improved. A preparation comprising the amorphous composition of the present invention has been found to be excellent in physical stability and chemical stability and to be useful as a nasal preparation or a preparation for adhering to the oral mucosa. As a result, the resulting preparation has a high BA value and is useful for prevention and/or the treatment of a disease mediated by the N type calcium channel including pain (such as neuropathic pain, cancerous pain, intractable pain, postoperative pain, acute pain, chronic pain, neuralgia and infectious pain).